

the acid hydrolyzate of natural tuberactinomycin N. Throughout the synthetic procedures, difficulties arising from especially labile character of β -ureidodehydroalanine part must be overcome by some device. In a preliminary experiment, β,β -diethoxyalanine,⁷⁾ which was prepared by acetalization of α -formylglycine, could be successfully used for peptide synthesis and converted into β -ureidodehydroalanine residue on the peptide chain at any synthetic step. Necessary fragments for total synthesis were prepared successively as mentioned in Fig. 2. Although DL-form of β,β -diethoxyalanine was used in this synthesis, diastereoisomers of the peptide intermediates have never been separated each other in any synthetic stages. A protected pentapeptide (1) was obtained by fragment condensation using dicyclohexylcarbodiimide-1-hydroxybenztriazole method at the side of carboxyl group of N^α -*t*-butoxycarbonyldiaminopropionic acid avoiding a possible racemization.

Ethyl ester of 1 was replaced with the active 1-succinimidyl ester (2) through saponification followed by reesterification. *o*-Nitrophenylsulfenyl (NPS) group in 2 was selectively removed under acidic conditions and the resulting pentapeptide ester was cyclized in pyridine at either 60°C or room temperature under high dilution condition to give cyclic peptide (3). [mp 250°C (decomp.), Found: C, 49.84; H, 7.47; N, 16.42 %, M.W. 811 (vapour pressure osmometry), Calcd for $C_{35}H_{62}O_{13}N_{10} \cdot H_2O$: C, 49.52; H, 7.60; N, 16.50 %, M.W., 849] The cyclization yield of about 25 % did not vary significantly depending on the reaction temperature. After removal of all protections except diethyl acetal from (3) by hydrogenolysis and then acidolysis, a solution of the peptide was refluxed in acetone-2M hydrochloric acid (1 : 1) for 10 min, and excess urea was added to afford an unprotected cyclic peptide (4) involving β -ureidodehydroalanine residue. The product thus obtained was identified with tuberactinamine N,⁸⁾ which was obtained from natural tuberactinomycin N, in all respects (Table 1). [Found: C, 36.76; H, 5.52; N, 24.79; Cl, 11.25 %, Calcd for $C_{19}H_{33}O_8N_{11}Cl_2 \cdot 1/2 H_2O$: C, 36.60; H, 5.50; N, 24.71; Cl, 11.37 %]. From the fact that the only single product was secured after addition of urea, the configuration of the double bond in β -ureidodehydroalanine part was found to be exclusively forced to Z configuration plausibly being controlled by the




Fig. 2




Fig. 3

Abbreviations; DCC: dicyclohexylcarbodiimide, HOSu: 1-hydroxysuccinimide, HOBT: 1-hydroxybenzotriazole, Z: benzyloxycarbonyl, Boc: *t*-butoxycarbonyl, Nps: *o*-nitrophenylsulfenyl, Cpd: capreomycin, Dea: β,β-diethoxyalanine, Uda: β-ureidodehydroalanine, Tua: tuberactinamine, Tum: tuberactinomycin

definite conformation, similar to the natural one, of the cyclic peptide moiety. To the peptide **4** thus obtained, β -lysine was introduced in the branched part as shown in Fig. 3. The final synthetic product was completely identical with natural tuberactinomycin O (Table 1). [Found: C, 38.18; H, 6.05; N, 22.84; Cl, 13.55 %, Calcd for $C_{25}H_{46}O_9N_{13}Cl_3 \cdot 1/2 H_2O$: C, 38.10; H, 6.01; N, 23.11; Cl, 13.50 %]

Table 1. Comparisons of Natural and Synthetic Compounds

| | | Tua N | | Tum O | |
|-----------------|---------------------------|-----------------------------------|-----------------------------------|-------------------------------|-------------------------------|
| | | synthetic | natural | synthetic | natural |
| mp | (decomp.) | 263-264° | 263-264° | 240-242° | 240-242° |
| $[\alpha]$ | (c 0.5, H ₂ O) | $[\alpha]_{365}^{18} -54.0^\circ$ | $[\alpha]_{365}^{18} -50.8^\circ$ | $[\alpha]_D^{16} -16.0^\circ$ | $[\alpha]_D^{16} -16.2^\circ$ |
| λ_{max} | H ₂ O | 268(26,600) | 268(22,000) ⁸⁾ | 268(25,500) | 268.5(23,800) ³⁾ |
| | 0.1M HCl | 268(26,700) | 268(22,000) ⁸⁾ | 268(26,500) | 269 (24,900) ³⁾ |
| | 0.1M NaOH | 285(17,000) | 286(14,000) ⁸⁾ | 286(17,400) | 288 (13,200) ³⁾ |

REFERENCES AND FOOTNOTES

* To whom correspondence should be addressed.

- 1) Part IX: T. Wakamiya and T. Shiba, *Bull. Chem. Soc. Jpn.*, **48**, 2502 (1975)
- 2) This study was presented at the 34th Annual Meeting of the Chemical Society of Japan, Kanagawa, April, 1976; p 699.
- 3) R. Izumi, T. Noda, T. Ando, T. Take and A. Nagata, *J. Antibiot.*, **25**, 201 (1972).
- 4) H. Yoshioka, T. Aoki, H. Goko, K. Nakatsu, T. Noda, H. Sakakibara, T. Take, A. Nagata, J. Abe, T. Wakamiya, T. Shiba and T. Kaneko, *Tetrahedron Lett.*, **1971**, 2043.
- 5) All component amino acids are of L-configuration, and β -ureidodehydroalanine part was assigned to Z-configuration.
- 6) T. Kitagawa, T. Ozasa, and H. Taniyama, *Yakugaku Zasshi*, **89**, 285 (1969).
- 7) "The Chemistry of Penicilin", Clarke, Johnson, and Robinson, Editors, Princeton University Press, Princeton, N. J., 1949, p.512.
- 8) T. Wakamiya and T. Shiba, *J. Antibiot.*, **28**, 292 (1975).